Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL

Sujan Piya, Yaling Yang, Seemana Bhattacharya, Priyanka Sharma, Huaxian Ma, Hong Mu, Hua He, Vivian Ruvolo, Natalia Baran, R. Eric Davis, Abhinav K. Jain, Marina Konopleva, Hagop Kantarjian, Michael Andreeff, M. James You, and Gautam Borthakur

The NOTCH1-MYC-CD44 axis integrates cell-intrinsic and extrinsic signaling to ensure the persistence of leukemia-initiating cells (LICs) in T-cell acute lymphoblastic leukemia (T-ALL) but a common pathway to target this circuit is poorly defined. Bromodomain-containing protein 4 (BRD4) is implicated to have a role in the transcriptional regulation of oncogenes MYC and targets downstream of NOTCH1, and here we demonstrate its role in transcriptional regulation of CD44. Hence, targeting BRD4 will dismantle the NOTCH1-MYC-CD44 axis. As a proof of concept, degrading BRD4 with proteolysis targeting chimera (PROTAC) ARV-825, prolonged the survival of mice in Notch1 mutated patient-derived xenograft (PDX) and genetic models (ΔPTEN) of T-ALL. Single-cell proteomics analysis from the PDX model, demonstrated quantitative reduction of LICs (CD34<sup>+</sup>CD7<sup>+</sup>CD19<sup>-</sup>) and downregulation of the NOTCH1-MYC-CD44 axis, along with cell cycle, apoptosis and PI3K/Akt pathways. Moreover, secondary transplantation from PDX and ΔPTEN models of T-ALL, confirmed delayed leukemia development and extended survival of mice engrafted with T-ALL from ARV-825 treated mice, providing functional confirmation of depletion of LICs. Hence, BRD4 degradation is a promising LIC-targeting therapy for T-ALL.

Leukemia (2022) 36:1261–1273; https://doi.org/10.1038/s41375-022-01516-1

INTRODUCTION

Treatment outcomes in patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL) as well as in certain high-risk subgroups of these patients, even with frontline therapy, are dismal and associated with the persistence of leukemia-initiating cells (LICs) [1–3]. Although phenotypic definition of LICs in the T-ALL patients is imprecise, CD34<sup>+</sup>CD7<sup>+</sup> cells are enriched in LIC compartment [4]. T-ALL LICs are functionally better characterized by high CD44 expression and low reactive oxygen species (ROS) levels [5–7]. Notch1, Myc, and CD44 have been implicated in persistence of LICs in T-ALL [3, 5, 8]. Substantial commonalities exist in pathways activated downstream of NOTCH1 and MYC in T-ALL [9]. Mutated Notch1 co-occupies the distal enhancer region of the MYC promoting activation of NFκB signaling, Hes1, PTEN, and PI3K/Akt pathways in a feed-forward loop circuit that supports leukemia cell growth, proliferation, and self-renewal [8, 10, 11]. Thus, MYC inhibition could represent a powerful therapeutic strategy to treat T-ALL with Notch1 mutation/activation. It has been difficult to target MYC directly, but MYC can be epigenetically downregulated by the disruption of members of the bromodomain and extra terminal domain (BET) protein family, enriched in large enhancer complexes (termed “super-enhancers”) [12–14]. BRD4, a BET family protein, binds to acetylated lysine residues in histone H3 and provides the scaffold to assemble multi-molecular super-enhancer complexes that drive expression of oncogenes, including Myc and antiapoptotic proteins such as Bcl-2, Bcl-xL, and Mcl-1 [13, 15, 16].

The bone marrow (BM) microenvironment is a protective niche for T-ALL and plays a critical role in chemoresistance and disease persistence [17, 18]. Stromal signaling includes chemokine and adhesion signals by SDF1-α/CXCR4, CD44 and its variants, and other stromal factors [19–21]. CD44, and even more so its variant CD44v8–10, are not only receptors for hyaluronic acid (HA) in the BM stroma but also known to stabilize SLC7A11/XCT, a subunit of the cystine-glutamate transporter XC (—) that promotes cystine uptake for glutathione synthesis and mitigates oxidative stress [22–24]. Reactive oxygen species (ROS) mitigation is essential for survival of T-ALL LICs [25], and a strategy to impair ROS mitigation through modulation of expression of CD44 and its variants, could help eliminate LICs.
ARV-825 is a proteolysis-targeting chimera (PROTAC) with three components: a thienodiazepine-based BRD4 ligand, a linker, and a cereblon-binding ligand. This chimera captures a BRD4 molecule and causes its proteasomal degradation via the E3 ligase cereblon. It is then available for degradation of additional BRD4 proteins [24, 26]. Previously, we reported that sustained degradation of BRD4 led to downregulation of CD44, MYC, and CXC4 in acute myeloid leukemia (AML) stem cells and improved survival in a mouse model of AML [24].

Given the central role of NOTCH1 and MYC in the pathogenesis of T-ALL and the necessity of CD44 and its variant CD44v8 for LICs to retain their ‘stemness’ by maintaining a state of low ROS levels, we report here our work with BRD4 degrader in patient-derived xenograft (PDX) and genetic models of T-ALL. We demonstrate that BRD4 regulates CD44 transcription and that degradation of BRD4 dismantles the NOTCH-MYC-CD44 regulatory circuits, depleting T-ALL LICs.

MATERIALS AND METHODS
T-ALL cell lines and PDX cells
The human leukemia cell lines CCRF-CEM, HPB-ALL, KOPT-K1, LOUCY, MOLT4, and SUP-T1 were purchased from the ATCC (Manassas, VA, USA) or Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany). The mouse T-ALL cell lines LPN228 and LPN49 were generated from conditional knockout mice deficient for Pten in T-lymphoid cells were treated with ARV-825 as described in the Supplemental Methods. The survival of the mice is represented by a Kaplan–Meier survival analysis (GraphPad Prism 7 software). Kaplan–Meier survival analysis was employed to compare the in vivo survival data using log-rank test. Normally distributed groups were compared by two-tailed Student’s t test. The statistical significance calculated as *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05 by a standard Student’s t test. In all cases, P values ≤ 0.05 were considered statistically significant.

RESULTS
BRD4 regulates NOTCH1, MYC, and CD44 expression in T-ALL and CD44 is a direct transcriptional target of BRD4
Our recent studies showed that pharmacological inhibition of BRD4 affects the expression of MYC, CD44, and Notch1 target genes in AML [24]. To obtain a global view of the transcriptional changes in T-ALL with the BRD4 degrader, here we performed genome-wide gene expression profiling (GEP) of SUP-T1 cells after treatment with ARV-825 for 24 h. The treatment resulted in downregulation of 729 genes and upregulation of 456 genes at a significant level (p ≤ 0.01) for a onefold change in the log2 value for treatment group. Several genes exhibited much larger fold changes as well (Fig. 1A upper panel). Gene set enrichment analysis (GSEA) using gene signatures from the Molecular Signatures Database highlighted the downregulation of Myc target genes along with gene sets representing other oncogenic pathways: cell-cycle progression, hypoxia response, metabolism, and Notch pathway activity (Fig. 1A bottom panel). Indeed, our gene expression data indicated that Myc and CD44 expression were downregulated upon ARV-825 treatment (Fig. 1B upper panel). Even though, Notch1 expression was partially upregulated, functional cleaved NOTCH1 (NICD) and its direct transcriptional target HES1, along with MYC and CD44 protein expression were deceased upon ARV-825 treatment (Fig. 1B bottom panel). Further, we analyzed NOTCH1, MYC, and CD44 genes in ALL-SIL and MOLT4 cells upon JQ1 (BRD4 inhibitor) treatment from publicly available gene set data GSE110634 [30] and GSE79253 [31] respectively and found that MYC and CD44 are downregulated (Fig. 1C).

To further confirm the association between BRD4 and these targets, we used CRISPR to knock out BRD4 in SUP-T1 and KOPT-K1 T-ALL cell lines (Supplementary Fig. 1A) and observed low expression of Myc and CD44 as well as that of CDK4 and CKD6 (Fig. 1D). BRD4 regulates transcription of Myc and Notch1, but whether BRD4 directly regulates chromatin state and CD44 expression is not known. To address this, we leveraged previously published ChIP-Seq data for BRD4 and histone marks at CD44 at KOPT-K1 [32] and identified high K4me1, K27ac and BRD4 peaks at the enhancer, ~16 kb upstream of CD44 and high K4me3, K27ac, and BRD4 peaks at the promoter (Supplementary Fig. S1B). Enrichment of these histone marks is strongly associated with BRD4-driven transcription. We performed ChIP-qPCR to validate BRD4-chromatin interactions at these loci in SUP-T1 cells (Fig. 1E and Supplementary Fig. S1B, C) and found that BRD4 was enriched both at enhancer and promoter of CD44 compared to CD44 gene body, an area of little to no enrichment (negative control) (Fig. 1E). In parallel, our ChIP-qPCR analyses revealed a strong enrichment of: H3K4me1 and H3K27ac (associated with active enhancer) on CD44 enhancer, H3K4me3 and H3K27ac (associated with active promoter) on CD44 promoter, and lack of H3K27me3 (associated with gene repression) at both enhancer and promoter compared to CD44 gene body (Fig. 1E and Supplementary Fig. S1B, C). Collectively, these results suggest that the CD44 gene is actively transcribed in SUP-T1 cells. Treatment with BRD4 degrader ARV-825 and small molecule inhibitor JQ1 reduced enrichment of BRD4, H3K4me1, H3K27ac and H3K4me3 on CD44 loci (Fig. 1E and...
Supplementary Fig. S1C). Taken together, these findings suggest that CD44 is a direct transcriptional target of BRD4.

**BRD4 regulates CD44/CD44v8-10 expression and modulates oxidative stress and oxidative phosphorylation in T-ALL**

In the context of AML, we showed that CD44 and its oncogenic variant CD44v8-10 are downregulated upon BRD4 degradation and this impairs cellular redox balance [24]. Similar to those findings, we found that BRD4 degradation by ARV-825 treatment resulted in pronounced downregulation of CD44 and CD44v8-10 mRNA in KOPT-K1 and SUP-T1 cells (Fig. 2A). Because CD44 and its variants stabilize SLC7A11/CT, a membrane cystine-glutamate antiporter that maintains low ROS levels in cells, we functionally correlated CD44 downregulation with oxidative stress. As shown in Fig. 2B, C (left), and Supplementary Fig. S2A degradation of BRD4 resulted in reduced surface expression of CD44, CD98, and...
BRD4 regulates NOTCH1, MYC, and CD44 expression in T-ALL and CD44 is a direct transcriptional target of BRD4. SUP-T1 cells were treated with ARV-825 (20 nM) for 24 h. RNA was isolated from the cells and subjected to gene expression profiling (GEP) \((n = 3)\). A GSEA was performed on Illumina GEP data and revealed high enrichment score (NES) \(> 3\), FDR q value \(< 0.05\) for several gene sets representing downregulation of Myc and Notch target gene sets along with oncogenic, cell-cycle, hypoxia, and metabolic pathways and upregulation of a gene set of the Wnt/Lβ-catenin and Jak/Stat pathways. B Upper panel: Illumina GEP data on SUP-T1 cells treated with ARV-825 for 24 h showed significant reduction MYC and CD44 while slightly upregulation of NOTCH1 genes. Lower panel: Immunoblots analysis of whole cell lysates (WCL) from SUP-T1 cells treated with ARV-825 (20 nM) for indicated time. C Upper panel-GSE110634(AILL-SIL) and lower panel GSE79253 (MOLT4) data were curated for NOTCH1, CD44, and MYC genes in ALL-SIL and MOLT4 treated with JQ1 respectively. \(\Delta\) Immunoblots of WCL of SUP-T1 and KOPT-K1 cells transduced with a nontargeted sgRNA (SgNT) or sgRNA targeting BRD4 (SgBRD4) using CRISPR/Cas9-GFP and then amplified single-cell clone #2 and clone #6, respectively, for different proteins. β-actin was used as a loading control. E ChIP-qPCR analysis reveal a significant reduction of BRD4 and H3K27ac occupancy at enhancer and promoter of CD44 in cells with ARV-825 and JQ1 (Supplementary Fig. S2G, H). The calculated inhibitory concentrations ranged from 14 to 125 nM as IC50 values, in a diverse array of T-ALL cells (Supplementary Fig. S2F). Importantly, in PDX-derived T-ALL cells with activating Notch1 mutations (TET2 mut, U2AF1 mut, WT1 mut), ARV-825 inhibited proliferation and induced apoptosis in bulk as well as in the CD34+ CD7+ LIC subset (Supplementary Fig. 2I).

BRD4 modulates Notch1, Myc, CD44, and PI3K/AKT signaling and apoptosis in T-ALL cells

We performed CyTOF analysis to simultaneously profile the status of multiple proteins associated with cell differentiation, survival, proliferation, metabolism, and homing and cell-cycle progression after treatment with ARV-825. In SUP-T1 cells, apart from downregulation of the known BRD4 targets like Myc, Bcl-2, Bcl-XL, and Mcl-1, treatment with ARV-825 substantially decreased the expression of key molecules involved in leukemia persistence, such as HES1 (a direct target of Notch1), PI3K/AKT pathway proteins, and CD44 (Fig. 3A left panel). We observed a similar CyTOF signature in KOPT-K1 cells (Fig. 3A right panel). To validate these findings, we performed immunoblotting with KOPT-K1 and SUP-T1 cells (NOTCH1 mutation) and LPN49 cells (PTEN mut, NOTCH1 mutation). Treatment with ARV-825 reduced the expression of Hes1, p-Akt, Cdk2/4/6, and Myc as well as the antiapoptotic proteins Bcl2, Mcl1, and Bcl-XL, resulting in increased cleaved PARP or caspase-3 expression at 24 and 48 h (Fig. 3B–D). These results confirmed that BRD4 modulates Notch1, Myc, CD44, and PI3K/AKT signaling and apoptosis in T-ALL cells.

ARV-825 has single-agent antileukemic activity and improves survival in mice with T-ALL and human T-ALL PDX

To test the therapeutic potential of BRD4 degradation for T-ALL, we used conditional knockout mice with T cell-specific PTEN deletion in which T-ALL developed and that had activating Notch1 mutations [35]. T-ALL establishment was confirmed by the appearance of immature blasts in the peripheral blood of mice (Fig. 4A) and was followed by administration of ARV-825 (20 mg/kg intraperitoneally twice a week. On day 14, ARV-825-treated mice had fewer circulating blasts than did the vehicle-treated mice, confirming the antileukemic effect of this agent (Fig. 4B and Supplementary Fig. S3A). Furthermore, we saw splenomegaly and thymomegaly associated with tissue infiltration of leukemic cells in vehicle-treated control mice but normal organ and architecture in ARV-825–treated mice (Supplementary Fig. S3B) on day 28. The antileukemic activity of ARV-825 resulted in markedly longer survival of ARV-825–treated mice than of vehicle-treated control mice (Fig. 4C median survival, 57 days vs. 17.5 days; \(p = 0.0039\)). We further validated the antileukemic activity of ARV-825 in a human PDX model of T-ALL. Immunodeficient NSG mice transplanted with D115 human T-ALL PDX cells (activating Notch1 mutations) were treated with ARV-825 (10 mg/kg intraperitoneally three times a week) or a vehicle on day 8 after confirmation of disease establishment (Fig. 4D upper panel). We confirmed reduction of the disease burden in ARV-825 treated mice via flow cytometric analysis of hCD45 in peripheral blood on day 35 (Fig. 4D bottom panel). We further demonstrated reduced hCD45+ cells in BM and spleens in ARV-825 treated mice compared to moribund
mice from vehicle group on day 38 (Fig. 4E). Indeed, histological examination of the BM and spleens from mice treated with ARV-825 revealed lower leukemia cell infiltration than in the vehicle group (Supplementary Fig. S3C top panel). Finally, in this aggressive T-ALL PDX model, mice in the ARV-825 cohort had significantly longer survival than did mice in the vehicle cohort (Fig. 4F; median survival time, 42 days vs. 38 days; \( p = 0.0042 \)). Indeed, above findings were confirmed in a repeat experiment using the same PDX model (\( n = 8 \), median survival 37 days vs. 31, \( p = 0.0004 \)) (Supplementary Fig. S3C-bottom panel).
To generalize the antileukemic activity of ARV-825, we further extended the in vivo study on a human CUL76 PDX (CDKN2A/B mut, Notch1 HD /PEST mut) model of T-ALL. After establishment of disease in NSG mice transplanted with CUL76 cells on day 10 (Fig. 4G upper panel), we administered ARV-825 (5 mg/kg intraperitoneally three times a week). As a vehicle, ARV-825 treated mice had lower leukemia burden by flow cytometric analysis of hCD45 in peripheral blood on day 19 (Fig. 4G bottom panel) and by reduced hCD45+ cells in BM and spleens on day 22 (Fig. 4H). While control mice showed splenomegaly, ARV-825-treated mice had normal organ weight and lower tumor burden by histological examination of the BM and spleens (Supplementary Fig. S3D). Finally, in this aggressive T-ALL PDX model, mice in the ARV-825 cohort had significantly longer survival than did mice in the vehicle cohort (Fig. 4; median survival time, 21 days vs. 35 days; p = 0.0019).

**Disruption of the Notch1-Myc-CD44 axis impairs LIC function and disease progression in mice with T-ALL**

The persistence of LICs drives relapse and therapy resistance of T-ALL. We performed single-cell proteomic analysis with CyTOF and Spanning-tree Progression Analysis of Density-normalized Events (SPADE; version 3.0) to study the expression of cell-surface and intracellular proteins in rare phenotypically defined subpopulations of T-ALL, including LICs, in BM samples of D115 PDX model from the above experiment. We clustered cell populations from BM hierarchically according to the expression of surface markers, and we displayed them in a single minimal spanning tree, where nodes can be annotated for further analysis as described previously [24]. The CD34+CD7+CD19− LIC subset clustered as a single node (cluster 1) in the tree (Fig. 5A left top panel). The expression of individual surface markers as well as intracellular proteins of interest in the SPADE tree for the mouse BM cell populations are presented in Fig. 5A. A heat map of the protein expression in LICs generated from a clustering tree with a single node demonstrated downregulation of NOTCH1-P13K/AKT-mammalian target of rapamycin (mTOR), CD44, and Myc in LIC nodes in ARV-825-treated mice (Fig. 5B, left and middle). In addition, proteins associated with cell-cycle progression and apoptosis were downregulated in these LICs while cyclin dependent kinase inhibitor, p21 was upregulated (Fig. 5B, right panel). Quantitatively, we observed a lower LIC number in ARV-825-treated mice (n = 38135) than in vehicle-treated mice (n = 66752).

To functionally validate the quantitative and qualitative impact of BRD4 degradation on T-ALL LICs, we performed serial transplantation from the experiment above using the D115 PDX model (Supplementary Fig. S4A). We transplanted equal numbers of FACSort-selected human cells from the BM of mice given ARV-825 or vehicle treated mice (0.25 x 10⁶ or 1 x 10⁶ hCD45+sorted cells; day 38), into NSG mice and monitored them for disease development and progression and overall survival without any further treatment. Mice that received either cell dose from ARV-825-treated donors had substantially lower circulating hCD45+ cell numbers in peripheral blood than did recipients of ALL cells from vehicle-treated mice (Fig. 5C, top and bottom). The mice injected with cells from the ARV-825-treated group also had considerably longer survival than did their vehicle-treated counterparts, with a median survival time of 58 days vs. 38 days (p = 0.00011) and of 50.0 days vs. 36.5 days (p = 0.0011) in mice injected with 0.25 x 10⁶ and 1 x 10⁶ cells, respectively (Fig. 5D, top and bottom). Secondary transplantation of BM cells under limiting dilution conditions (10⁴ to 10⁶ cells/mouse) into secondary transplant recipients revealed an LIC frequency of 1 in 175126 cells for vehicle-treated mice and 1 in 645252 cells (p = 0.054) ARV-825-treated mice (Fig. 5E, Table 1). In mice in the vehicle group in secondary transplantation showed higher burdens of leukemic CD45+ cells in blood, BM, and the spleen (Table 1).

In concordance with our cell line data and PDX data, in the conditional Pten-deficient T-ALL mouse model, we observed reduction in the expression of BRD4, surface CD44, HES1 (a direct target of Notch1), and MYC in BM T-ALL cells from the ARV-825-treated mice (Fig. 5F upper and lower panel). Furthermore, we validated impaired LIC function in this model also with secondary transplantation (Supplementary Fig. S4B). Mice that received BM from the ARV-825 treated group exhibited lower numbers of circulating blasts than from the vehicle-treated group on day 30 (Fig. 5G). Finally, mice receiving cells from the ARV-825-treated group had a markedly longer median survival time than did their vehicle-treated counterparts (58 days vs. 31 days, p < 0.0001) (Fig. 5H). Infusion of BM cells into secondary transplant recipients resulted in LIC frequency of 1 in 423795 in vehicle-treated mice and 1 in 1268381 (p = 0.04) in ARV-825-treated mice (Fig. 5I, Table 1). These findings confirmed the therapeutic role of BRD4 degradation in targeting in T-ALL LICs.

**ARV-825 synergizes with inhibitors of Wnt/β-catenin and Jak/Stat pathways**

Alteration of Wnt/β-catenin and Jak/Stat pathways is important in the pathobiology of T-ALL. Importantly, GSEA revealed upregulation of the Jak/Stat and Wnt/β-catenin pathway target genes Axin-2 and Fra1 in SUP-T1 and KOPT-K1 cells treated with ARV-825 (Fig. 6A top and bottom panel respectively). In marked contrast with our previous report in AML cells [24], surface expression of CXCR4 was upregulated in both cell lines in response to ARV-825 (Fig. 6B). These findings have translational therapeutic potential, as high surface CXCR4 expression, and Wnt signaling are required for T-ALL LIC activity [36, 37]. It should be noted that unlike in AML CXCR4 is regulated by calcineurin in T-ALL, not by PIM1 kinase [36]. Combination treatments with the Wnt/β-catenin inhibitor CCT251545 or the CXCR4 inhibitor BL-8040 had synergistic effects on apoptosis induction in T-ALL cells when we cultured them either alone (monoculture) or with BM-derived mesenchymal stromal cells (co-culture) to mimic the BM environment (Fig. 6C, D), demonstrating translational potential.
Fig. 3  BRD4 modulates Notch1, Myc, CD44, and PI3K/AKT signaling and apoptosis in T-ALL cells. A SUP-T1 and KOPT-K1 cells treated with ARV-825 (20 nM and 50 nM) for 24 h and subjected to mass spectrometry-based flow cytometry (CyTOF). The heat map was generated using Prism software (version 8; GraphPad Software, San Diego, CA, USA). B KOPT-K1, C SUP-T1 and mouse (D) T-ALL LPN49 cells treated with ARV-825 in concentration 50 or 20 nM or 15 nM respectively for 24 h. Whole-cell lysates were analyzed using the indicated antibodies. β-actin was used as a loading control. β-actin used as a loading control.
Fig. 4 ARV-825 has single-agent antileukemic activity and improves survival in mice with T-ALL. A 8-week-old Pten-deficient mice with T-ALL as indicated by the appearance of immature blasts in peripheral blood consider as day 0 and randomly assigned to treatment with a vehicle or ARV-825 (20 mg/kg intraperitoneally twice a week) (n = 8). B After 14 days of treatment, reduction of disease burden in ARV-825 compared to vehicle group documented as reduced immature blast in blood. C Kaplan–Meier survival curve for mice with T-ALL treated with ARV-825 or a vehicle (p = 0.0089). D Six-week-old NSG mice were implanted with D115 T-ALL PDX cells (1 × 10^6) through the tail vein (n = 10). Leukemia engraftment was confirmed on day 8 via detection of hCD45+ cells in peripheral blood (upper panel) and randomly assigned to treatment with either ARV-825 (10 mg/kg). The reduced leukemia burden in ARV-825 treated mice compare to vehicle as seen via flow cytometric analysis of hCD45 in peripheral blood on day 19 (lower panel). E On day 38, reduced leukemia burden as expression of hCD45 on bone marrow and spleen in ARV-825 treated mice compare to vehicle. F Kaplan–Meier survival curve for mice with T-ALL treated with a vehicle or ARV-825 (p = 0.0042). G NSG mice were implanted with CUL76 T-ALL PDX cells and monitored for 10 days (n = 6). Peripheral blood of mice was subjected to flow cytometry analysis to check expression of hCD45 to document engraftment of leukemia and then treated with vehicle, ARV-825 (5 mg/kg) or vehicle as above (upper panel). The reduced leukemia burden in ARV-825 treated mice compare to vehicle as seen via flow cytometric analysis of hCD45 in peripheral blood on day 19 (lower panel). H On day 22, reduced leukemia burden as expression of hCD45 on bone marrow and spleen in ARV-825 treated mice compare to vehicle. I Kaplan–Meier plot of the in vivo activity of ARV-825 against CUL76 PDX engrafted with NSG mice. Significance between ARV-825-treated vs. vehicle-treated mice was determined by a Mantel–Cox Rank Sum test. P values < 0.05 were considered to be significant.

DISCUSSION

Despite high rates of remission with current frontline therapy, a large proportion of patients with T-ALL, particularly adults, experience relapses with dismal outcomes, with <10% of patients surviving over the long term [1, 9, 38]. LICs represent a reservoir of this disease [39]. Notch1, Myc, and CD44 are implicated to have a role in the persistence of these LICs in T-ALL cases [3, 5, 8]. The present study provides evidence that BRD4 is a common therapeutic target that can disrupt the Notch1, Myc, and CD44 pathways to effectively eliminate the T-ALL LICs.

Mutations in the negative regulatory domain of NOTCH1 lead to NOTCH1 activation, and are present in up to 60–70% of patients with T-ALL [40]. In addition, inactivating mutations of FBXW7, which is involved in proteasomal degradation of NOTCH1, are present in 15% of T-ALL cases [9, 41, 42]. Mutated NOTCH1 drives MYC expression and deletion of a copy of the NOTCH-bound MYC enhancer N-Me, extends survival in a NOTCH1-driven T-ALL model.
Additional genetic events leading to leukemogenesis in T-ALL cases include loss of the tumor suppressor PTEN; loss of the cell-cycle inhibitors CDKN2A, RB, and CDKN1B; and increased expression of the transcription factors TAL1, LMO1, LMO2, TLX1, and TLX3 and the oncogene MYC [11, 40, 43]. CD44 upregulation also contributes to leukemogenesis and LIC persistence in T-ALL patients [5] and has been identified as a NOTCH1 transcription target. Herein we show that CD44 transcription can be targeted by
Fig. 5  Disruption of the Notch1-Myc-CD44 axis impairs LIC function and disease progression in mice with T-ALL. BM cells were collected from vehicle- and ARV-825–treated mice with D115 T-ALL PDXs on day 38 from above experiment in Fig. 4 and (A) subjected to CyTOF, and the resulting data were analyzed using SPADE (version 3.0). The spanning tree was generated according to the expression of CD34, CD7, and CD19. B Expression of proteins related to the Notch pathway, Myc activity, the PI3K/AKT/mTOR pathway, cell cycle/apoptosis, and the tumor microenvironment in BM cells from vehicle- and ARV-825–treated mice was determined and quantified in LICs (CD34+CD7+CD19− subset; cluster 1). The heat maps were generated using Prism software (version 8) based on the intensities of proteins in vehicle- and -treated mice. C Duplicate BM cells from mice treated with ARV-825 or a vehicle from the experiment in Fig. 4 were transplanted into NSG mice at two dilutions (0.25 and 1 million cells). The graphs compare the leukemia burden in peripheral blood at day 22 on mice as lower dose (upper panel) and higher dose (lower panel) (D) corresponding Kaplan–Meier survival curves for mice with the indicated numbers of cells. E LIC frequencies in NSG mice according to limiting dilution transplantation analyses. The dotted lines indicate 95% CIs. F BM cells were collected from vehicle- and ARV-825–treated conditional Pten-deficient T-ALL mice on day 28. The bone marrow from above experiment (Fig. 4) in the conditional Pten-deficient T-ALL mouse model which exhibited reduced surface expression of the surface CD44 (top panel) by flow cytometry and also reduced expression of BRD4, HES1, and MYC in ARV-825 treated group in immunohistochemical (IHC) staining (Bottom panel). Duplicate of the same from those experiment, 1 × 10⁶ bone marrow cells were transplanted to 4.5 Gy irradiation normal mice and (G) after 30 days leukemia burden was measured and exhibited reduced circulating immature blast counts in mice given ARV-825. H Kaplan–Meier survival curve for the secondarily transplanted mice with T-ALL treated with ARV-825 or a vehicle (p < 0.0001). I LIC frequencies in the mice in the secondary transplantation analyses. The dotted lines indicate 95% CIs.

BRD4 degradation. BRD4 binds to both the promoter and enhancer of CD44, regulating the transcription of CD44 in T-ALL cells. In addition, BRD4 degradation downregulates Myc and active Notch1 (NICD), which are critical to the development of T-ALL. Hence, the present work confirms that the bromodomain and extraterminal domain family protein BRD4 is a therapeutically actionable transcripational target in T-ALL with clinically relevant mutations.

Recent therapeutic efforts for T-ALL have relied heavily on targeting mutant Notch1 and its activating events with gamma secretase inhibitors and have been limited by on-target toxic effects [44]. In contrast, our work with the BRD4 degrader ARV-825 is focused on downregulation of NOTCH1 targets and cell-intrinsic pro-survival and/or antiapoptotic proteins as well as interaction with BM microenvironment interactions. Mechanistically, the data from the present study link degradation of BRD4 with transcriptional downregulation of CD44 and its variants, increasing oxidative stress. Using conditional Pten-deficient T-ALL mouse model and NOTCH1-mutated disseminated T-ALL PDX models, which recapitulate several features of human T-ALL biology, we showed that disruption of the NOTCH1-MYC-CD44 axis interferes with the maintenance of leukemia by targeting the LIC population. Indeed, single-cell proteomic analysis of BM cells of ARV-825–treated mice using CyTOF revealed marked downregulation of NOTCH1, MYC, and CD44 along with a significant quantitative decrease in the phenotypically defined LIC population. Furthermore, we demonstrated that reduction in the overall LIC population resulted in extended survival of mice after secondary transplantation. Although the genetic mouse model used in our study has a Pten deletion, these mice often have secondarily acquired activating NOTCH1 mutations [35]. Our findings show the common role of BRD4 in the NOTCH1-, MYC-, and CD44-regulatory axis and we propose that BRD4 is a single target that can be used to disrupt all these pathways simultaneously eliminating T-ALL LICs.

Although we identified BRD4 degradation as a therapeutic means of eliminating T-ALL LICs, our gene array data raise concerns about upregulated CXCR4, other microenvironment niche molecules, and Wnt/β-catenin signaling after BRD4 degradation. These findings may point to potential mechanisms of resistance for bromodomain and extraterminal domain degraders when tested for treatment of T-ALL in clinical trials. Our preliminary work provides guidance toward the use of therapeutic combinations, including inhibition of Wnt/β-catenin signaling or CXCR4 expression to overcome these potential resistance mechanisms (Fig. 6). In our AML study, we showed that BRD4 degradation results in downregulation of surface CXCR4 through downregulation of PIM1 kinase, which phosphorylates CXCR4 [24]. In contrast, CXCR4 expression was not impacted in T-ALL cells, likely because of calcineurin-mediated control of CXCR4 expression in these cells [36].
Fig. 6 ARV-825 synergize with inhibitor of Wnt/β-catenin and Jak/Stat pathways. SUP-T1, KOPT-K1, and OCIAML3 cells were treated with ARV-825 in concentration 20 nM, 50 nM, and 10 nM respectively for 24 h. A qPCR analysis of the Axin2 and Fra-1 in three independent samples of SUP-T1 and KOPT-K1. Cxcr4 in three independent samples KOPT-K1. B surface expression of CXCR4 in the SUP-T1, KOPT-K1, and OCIAML3 cells was detected using flow cytometry. C and D ALL cell lines SUP-T1 and KOPT-K1 were cultured with or without mesenchymal stromal cells and treated with ARV-825, CCT251545, or BL-8040 alone or combined for 72 h. The percentage of apoptosis of the cells was calculated using annexin V staining with flow cytometry. Error bars represent SD from three different biological replicates (*p < 0.05, **p < 0.01, ***p < 0.001 compared to DMSO.)
REFERENCES

1. Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol/Educ Prog Am Soc Hematol Am Soc Hematol Educ Program. 2016;2016:580–8.

2. Lang F, Wojck B, Rieger MA. Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia. Stem Cells. Int. 2015;2015:137164.

3. Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, Calvo J, Fontenay M, et al. NOTCH1 is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009;113:1730–40.

4. Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S, et al. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia. 2011;25:1249–58.

5. Garcia-Peyro M, Fuentes P, Mosquera M, Garcia-Leon MJ, Alcain J, Rodriguez A, et al. The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model. J Clin Investig. 2018;128:2802–18.

6. Lagadinos ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minjahujidin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329–41.

7. Trentin L, Quedevelle M, Eckhoff SM, Hasan N, Munch V, Boldrin E, et al. Leukemia reconstitution in vivo is driven by cells in early cell cycle and low metabolic state. Haematologica. 2018;103:1008–17.

8. Schubbert S, Cardenas A, Chen H, Garcia C, Guo W, Bradner J, et al. Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia. Cancer Res. 2014;74:7048–59.

9. Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecular biology of T-ALL. Blood. 2017;129:1113–23.

10. Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med. 2014;20:1130–7.

11. Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukemia. Nat Rev Cancer. 2016;16:494–507.

12. Delmore JE, Iacovella J, Rieger MA. Stem Cell Hierarchy and Clonal Evolution in Acute Leukemia. J Clin Investig. 2018;128:2802–18.

13. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of chromatin. Adv Biol Regul. 2014;56:6

14. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-rearrangement acute myeloid leukemia. Nat Med. 2015;21:3917–27.

15. Pui CH, Carroll WL, Meschenich S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:551–65.

16. Martelli AM, Lonetti A, Buontempo F, Ricci F, Tazzari PL, Evangelisti C, et al. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. Adv Biol Regul. 2014;56:6–21.

17. Sanchez-Martin M, Ferrando A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Blood. 2017;129:1124–34.

18. King B, Trimmer T, Ravei L, Xu L, Mullenders J, Ntzaichristos P, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013;153:1522–66.

19. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematol/Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2009:353–61. https://doi.org/10.1182/asheducation-2009.1353.

20. Gutierrez A, Sando T, Ma W, Zhang J, Grebliouaite R, Dahlberg S, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010;115:2845–51.

21. van ES JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:993–6.

ACKNOWLEDGEMENTS

The authors thank Marina Konopleva and M. James You for T-ALL PDX support, Jared K Burks and Duncan H. Mak for flow cytometry and cellular imaging and Sung-Ho Goh for (Precision Medicine Branch, Research Institute, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea) for CD44 and CD44v8-10 with a GFP-tagged pHRST lentiviral vector. Konopleva and Andreeff laboratory members for help with experiments and suggestions, and Nunsen M. Hail Jr. for editing and correcting the paper.

AUTHOR CONTRIBUTIONS

Concept and design: SP, GB. Development of methodology: SP and GB. Acquisition of Data: SP, SB, NB, YY, SS, and ED. Animal experiment: SP, HM, and YY. Writing of paper: SP and GB. Review and/or revision of paper: SP, GB, MA, and MJY, YY, ED, VR, SB, and MK. Administrative and Material supports, core facility: HM, HH, VR, and AJ. Epigenomics Profiling Core and Flow Cytometry & Cellular Imaging Core Facility, MD Anderson Cancer center.

FUNDING

This work was supported in part by the NIH/NIH under award number P30CA016672 for the Cancer Prevention & Research Institute of Texas (RP121010), the Paul and Mary Haas Chair in Genetics (to MA), an MD Anderson Internal Research Grant (to MJY and GB), and Arvinsa, Inc. (to GB).
COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL
We complied fully with regulations for ethical treatment of animals, and the experiments were approved by our institutional IACUC at MD Anderson Cancer Center.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41375-022-01516-1.

Correspondence and requests for materials should be addressed to Sujan Piya, M. James You or Gautam Borthakur.

Reprints and permission information is available at http://www.nature.com/reprints

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022